US Stock MarketDetailed Quotes
GYRE Gyre Therapeutics
- 13.100
- -1.330-9.22%
Close May 21 16:00 ET
1.12BMarket Cap-12768P/E (TTM)
14.210High12.830Low68.23KVolume14.210Open14.430Pre Close904.45KTurnover0.43%Turnover RatioLossP/E (Static)85.51MShares30.40052wk High19.79P/B205.88MFloat Cap3.15052wk Low--Dividend TTM15.72MShs Float5798.166Historical High--Div YieldTTM9.56%Amplitude0.854Historical Low13.255Avg Price1Lot Size
About Gyre Therapeutics Company
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
Company Profile
SymbolGYRE
Company NameGyre Therapeutics
Listing DateApr 12, 2006
Founded1997
CEODr. Han Ying, PhD
MarketNASDAQ
Employees4
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address12770 High Bluff Drive,Suite 150
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92130
Phone1-619-949-3681
Websitehttp://www.gyretx.com
Company Executives
- Name
- Position
- Salary
- Dr. Han Ying, PhD
- Director and Chief Executive Officer
- 21.08K
- Weiguo Ye
- Chief Operating Officer
- 274.62K
- Ruoyu Chen
- Chief Financial Officer and Principal Accounting Officer
- 208.16K
- Songjiang Ma
- Director and President
- --
- Dr. Ying Luo, PhD
- Chairman of the Board
- 24.74K
- Thomas Eastling
- Director
- 1.88M
- Rodney L. Nussbaum
- Director
- --
- Dr. Gordon G. Carmichael, PhD
- Independent Director
- 19.24K
- Dr. Renate Parry, PhD
- Independent Director
- 19.91K
- Dr. Nassim Usman, PhD
- Independent Director
- 1.88M
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg